Biocare Medical LLC

Biocare Medical LLC, a California-based manufacturer of immunohistochemistry products and automated medical diagnostic equipment, operates exclusively as a prime contractor (100% of recent awards) supplying federal health agencies with laboratory instruments, reagents, antibodies, and maintenance services under full-and-open competition — the vendor holds no SBA set-aside designations, with the single exception of a Total Small Business purchase order from the Food and Drug Administration in June 2024 for an IHC autostainer valued at $133,043.

Biocare Medical is structured as a for-profit limited liability company and manufacturer of goods headquartered in Pacheco, California. The vendor's capability portfolio centers on immunohistochemistry automation and diagnostics: IntelliPath and ONCORE PROX automated slide staining systems; IHC reagents, antibodies, and decloaking chambers; and five-year preventive maintenance agreements supporting laboratory operations across the federal health system. Representative work includes a $147,975 firm-fixed-price purchase order from the Office of Administrative Services for an IntelliPath+ system and preventive maintenance agreement in Athens, Georgia (awarded September 2024, completing September 2029); a $144,000 purchase order from the National Institute on Aging for an ONCORE PROX automated slide staining system (May 2024); and a $225,275 purchase order from the Defense Health Agency for medical antibodies for laboratory use, Bethesda, Maryland (March 2024, completing March 2027).

Customer concentration across the top three agencies by potential value — Defense Health Agency ($7 million across 9 awards), Department of the Army Medical Command ($1.9 million across 6 awards), and Department of Veterans Affairs Veterans Integrated Service Network 6 ($1.9 million across 16 awards) — accounts for 75% of combined potential value. The vendor has worked with 30 distinct customer agencies over the source window, with significant recurring demand from NIH agencies (National Cancer Institute, National Institute on Aging, National Institute of Environmental Health Sciences) and CDC Pittsburgh. Biocare Medical places the plurality of its work through two GSA Federal Supply Schedules (GS07F0029U with 15 task orders, $713 thousand; GS07F0030U with 7 task orders), supplemented by smaller volumes under blanket purchase agreements and indefinite delivery contracts with Army Medical Command and other DOD health components.

Activity has been sparse in recent years — one award in 2025 and one in 2026 — following three awards in 2024 and a valley of two awards in 2023. The vendor has secured 449 prime awards since 2002, with $16.1 million in combined potential value across all awards and $5.7 million in combined obligated dollars (35% draw-down rate). Three awards (combined potential value $296 thousand) face ultimate completion within the next twenty-four months, creating limited recompete exposure in the near term. NAICS and PSC concentration aligns tightly with the award profile: 72 awards under In-Vitro Diagnostic Substance Manufacturing (NAICS 325413), 17 under equipment repair and maintenance, and 144 under PSC codes for in-vitro diagnostic substances and reagents.

histology related reagents, antibodies, detection systems, buffers, solutions,and other related products used by diagnostic and research centers for the diagnosis of cancer and other infectious diseases